Health Professional Radio - Podcast

Dr. Janelle Sabo, Global Therapeutics Platform Leader at Eli Lilly & Company discusses COVID-19 monoclonal antibody treatments and how if given within 10 days of symptoms appearing can decrease the risk of hospitalization and/or disease progression in appropriate patients and having a plan of action should a high-risk individual test positive. Dr. Janelle A. Sabo, PharmD, RPh, MBA is a recognized leader in drug development, clinical research and product delivery. Her unique background has driven a strong patient focus and desire to find innovative ways to deliver faster new therapies to patients and the global medical community. Janelle is a senior leader at Eli Lilly and Company enabling drug development and commercialization. Additionally, Dr. Sabo currently leads the global Covid-19 Therapeutics Platform. Janelle has extensive drug development experience including leading, portfolio management, and project management organizations. She also has held senior leadership roles in clinical research, global